Company revenue is concentrated in AMVUTTRA sales for ATTR-CM following March 2025 FDA approval; failure to grow these revenues would materially harm results.
Relevance 95·Dependency 90·Confidence 97
Source evidence
“our business is dependent upon our ability to sustain and grow revenues from sales of AMVUTTRA”
RNAi therapeutics platform
Technology Dependency
All approved products and pipeline candidates derive from the RNAi platform; pipeline expansion into additional tissue types underpins growth.
Relevance 90·Dependency 90·Confidence 90
Source evidence
“our views with respect to the clinical and commercial potential of (including the potential numbers of patients who may benefit from) our approved and investigational RNAi therapeutics”
AMVUTTRA's commercial expansion depends on securing ATTR-CM approval in additional jurisdictions beyond FDA, EC, PMDA and MHRA.
Relevance 90·Dependency 85·Confidence 90
Source evidence
“AMVUTTRA has been approved by the FDA, EC, PMDA, MHRA and certain other regulatory authorities for the treatment of ATTR-CM, regulatory authorities in other jurisdictions have not yet granted approval for this expanded indication”
U.S. Food and Drug Administration
Regulatory Exposure
FDA approval is required for commercialization; agency funding shortfalls and shifting priorities could delay reviews, and past CRL (patisiran ATTR-CM) demonstrates approval uncertainty.
Relevance 90·Dependency 85·Confidence 95
Source evidence
“Inadequate funding for the FDA and other government agencies and/or potentially shifting priorities under the current administration could hinder the agencies’ ability to hire and retain key leadership and other personnel”
AMVUTTRA (vutrisiran)
Demand Driver
AMVUTTRA approval for ATTR amyloidosis with cardiomyopathy in additional jurisdictions is a key growth lever; company explicitly ties future outlook to its regulatory expansion.
Relevance 90·Dependency 85·Confidence 90
Source evidence
“our ability to obtain regulatory approval of AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy in additional jurisdictions outside the United States”
Third-party CMOs
Supplier Dependency
All drug product requirements for clinical and commercial use are manufactured by a limited number of CMOs; CMO failure risks commercial supply.
Relevance 85·Dependency 85·Confidence 95
Source evidence
“we rely on third party CMOs for all of our drug product requirements for clinical and commercial use”
siRNA delivery technology
Technology Dependency
Commercial success depends on maintaining leadership in siRNA delivery to relevant cell and tissue types; competitors may lock up exclusive third-party delivery solutions.
Relevance 85·Dependency 80·Confidence 93
Source evidence
“if our competitors negotiate exclusive access to delivery solutions developed by third parties, we may be unable to successfully commercialize our product candidates”
nucresiran
Competitive Exposure
Nucresiran ATTR-CM enrollment competes against multiple approved and investigational ATTR-CM therapies, threatening development timelines.
Relevance 85·Dependency 70·Confidence 95
Source evidence
“we may experience delays in recruiting and enrolling patients, and in particular treatment-naive patients, for our Phase 3 clinical trial of nucresiran for the treatment of ATTR-CM because there are multiple approved therapies on the market”
Interest expense on royalty-sale/development funding debt is tied to estimated AMVUTTRA global net revenues, exposing financing costs to AMVUTTRA's commercial performance.
Relevance 80·Dependency 70·Confidence 90
Source evidence
“using third-party data to estimate Leqvio's and AMVUTTRA's global net revenues”
Healthcare reform / pricing and reimbursement
Revenue Exposure
Healthcare reforms affecting pricing, government price reporting, payment, insurance coverage and reimbursement directly affect product revenue.
Relevance 80·Dependency 70·Confidence 85
Source evidence
“the impact of current and potential healthcare reforms, including those affecting the delivery, pricing or government price reporting of, or payment, insurance coverage or reimbursement for, healthcare products and services”
Interest expense on royalty-sale/development funding debt is tied to estimated Leqvio global net revenues, exposing financing costs to Leqvio's commercial performance.
Relevance 80·Dependency 70·Confidence 90
Source evidence
“using third-party data to estimate Leqvio's and AMVUTTRA's global net revenues”
Drug pricing regulation
Regulatory Exposure
MFN pricing, U.S. government drug price negotiation, and payor reimbursement restrictions could reduce net price of AMVUTTRA and other products.
Relevance 80·Dependency 70·Confidence 90
Source evidence
“drug price control measures that have been or may be enacted or introduced in the U.S. by various federal and state authorities”
Ionis Pharmaceuticals
Competitive Exposure
Ionis markets approved antisense drugs (WAINUA/inotersen) for hATTR using Alnylam-licensed GalNAc technology, competing directly in amyloidosis.
Relevance 80·Dependency 60·Confidence 95
Source evidence
“Ionis is also developing antisense drugs using ligand-conjugated GalNAc technology licensed from us, and these drugs have been shown to have increased potency at lower doses in clinical and preclinical studies”
Contract manufacturers
Supplier Dependency
Manufacture and supply of commercial products depends on the company and its contract manufacturers; failures would interrupt product supply.
Relevance 75·Dependency 70·Confidence 85
Source evidence
“delays, interruptions or failures in the manufacture and supply of AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO or any of our product candidates (or Leqvio, Qfitlia, cemdisiran or other products or product candidates being developed and commercialized by our collaborators), by our or their contract manufacturers or by us or our collaborators”
mivelsiran
Regulatory Exposure
Partial clinical hold on mivelsiran Phase 1 in the U.S. could impact development timelines if plans change.
Relevance 75·Dependency 70·Confidence 95
Source evidence
“it is possible that the partial clinical hold could have an impact if our development plans change or that future partial or full clinical holds on mivelsiran or our other product candidates could impact our ability to advance the clinical development”
GalNAc
Technology Dependency
Alnylam supplies GalNAc material commercially to collaborators, linking collaboration cost structure to its GalNAc delivery platform.
Relevance 75·Dependency 65·Confidence 85
Source evidence
“costs we incur in connection with providing commercial drug supplies, such as GalNAc material, to collaborators”
Arrowhead Pharmaceuticals
Competitive Exposure
Arrowhead competes in siRNA therapeutics and holds exclusive licenses to certain Alnylam technology for 30 gene targets via Novartis assignment.
Relevance 75·Dependency 55·Confidence 95
Source evidence
“Arrowhead, as the assignee of Novartis, has obtained specific exclusive licenses for 30 gene targets, that include access to certain aspects of our technology”
siRNA delivery technology (LNPs, conjugates)
Technology Dependency
Specialized/proprietary delivery technologies may be manufacturable by only one or a limited number of suppliers, creating supply risk.
Relevance 70·Dependency 70·Confidence 88
Source evidence
“we may have access to only one or a limited number of potential manufacturers for such delivery technology”
Collaboration partners (Leqvio, Qfitlia, cemdisiran)
Revenue Exposure
Collaborations supply R&D funding, licensing fees, milestones and royalties; maintaining these agreements supports non-product revenue.
Relevance 70·Dependency 55·Confidence 85
Source evidence
“our ability to maintain our existing collaborations and our expectations regarding potential future research and development funding, licensing fees and milestone and royalty payments that we may receive under existing or future collaboration agreements”
BIOSECURE ACT
Regulatory Exposure
BIOSECURE ACT could restrict purchasing from or collaborating with Chinese biotech companies of concern; Alnylam does business with companies in China.
Relevance 70·Dependency 50·Confidence 90
Source evidence
“The BIOSECURE ACT has the potential to severely restrict our ability to purchase services or products from, or otherwise collaborate with, certain Chinese “biotechnology companies of concern””
Pharmaceutical tariffs
Cost Driver
Potential tariffs of 100%+ on pharmaceuticals could increase cost of goods sold and disrupt suppliers.
Relevance 65·Dependency 40·Confidence 88
Source evidence
“any unfavorable tariffs may increase our cost of goods sold”
Indebtedness / convertible notes service
Cost Driver
$1.02 billion of convertible Notes require future cash flow for principal, interest and conversion payments; business may not generate sufficient cash flow.
Relevance 60·Dependency 55·Confidence 90
Source evidence
“Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the Notes, or to make cash payments in connection with any conversions of Notes, depends on our future performance”
Novartis commercializes Leqvio under collaboration terminable on four months' notice; termination would require Alnylam to find a new collaborator or build internal commercialization.
Relevance 60·Dependency 50·Confidence 92
Source evidence
“Our agreement with Novartis relating to the development and commercialization of Leqvio worldwide may be terminated by Novartis at any time upon four months’ prior written notice”